Return to About
  Board of Directors

Alastair Summerlee LLD, PhD, BVSc, BSc, MRCVS – President Summerlee, whose career as a scholar, professor, researcher and administrator spans nearly 30 years, joined the University of Guelph faculty in 1988 as a professor in the Department of Biomedical Sciences. He was named an associate dean of the Ontario Veterinary College in 1992, dean of graduate studies in 1995, associate vice-president (academic) in 1999, and provost and vice-president (academic) in 2000. He has continued teaching while holding administrative positions and was awarded a prestigious 3M Teaching Fellowship in June, 2003 for outstanding leadership in teaching, education and academic program development. He is the only University of Guelph professor to earn the honour while serving as an administrator and is the first president-elect in Canada to be named a 3M Fellow. He was also recognized with a Distinguished Professorial Teaching Award from the U of G Faculty Association in 1991. In 2006, Dr. Summerlee was named as the chair of the board of directors of World University Service of Canada (WUSC), one of the country's leading international development agencies. WUSC teams with students, faculty and institutions to internationalize Canada’s universities, increase knowledge of global issues and foster human development through education and training. His research in biomedical sciences is acclaimed internationally and he has attracted significant money to support his research, published extensively and been an invited lecturer at universities and colleges around the world. He holds a B.Sc., B.V.Sc. and Ph.D. from the University of Bristol in the United Kingdom and is a member of the Royal College of Veterinary Surgeons. In 2004 Dr. Summerlee received the Doctor of Laws (Honoris causa) from the University of Bristol.

Dr. John Trachtenberg MD, FACS, FRCSC – Dr. John Trachtenberg received his B.Sc., M.D. & C.M. from McGill University in Montreal. He completed his urologic residency at McGill University and then a fellowship in prostatic disease at Johns Hopkins University. Dr. Trachtenberg is currently Professor of Surgery and Medical Imaging at the University of Toronto. He holds the prestigious Fleck Tanenbaum Chair in Prostatic Diseases at the University of Toronto and University Health Network. He is the Director of the Prostate Centre at the Princess Margaret Hospital of the University Health Network. He acts as a consultant to the Urology Department at several other hospitals, as well as the Ontario Cancer Foundation. Dr. Trachtenberg has published over 200 peer reviewed scientific papers and several books, and sits on many hospital, university and scientific committees throughout North America and Europe. His accomplishments have earned him 18 awards, including Man of the Year in Sciences and Medicine from the Canadian Prostate Cancer Research Fund. He has developed novel, minimally invasive surgical techniques for the treatment of prostate cancer and was instrumental in the development of the prostate specific Clinical Research Program at the Princess Margaret Hospital. His major interests include developing image guided treatments for prostate cancer and the quality of life of men with prostate cancer.

Dr. Anthony Joshua, MBBS, PhD – Dr. Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto to complete a PhD under the supervision of Dr. Jeremy Squire in prostatic carcinogenesis. He has since joined the Department of Medical Oncology at The Princess Margaret, specialising in genito-urinary malignancy and melanoma. He is currently an Assistant Professor with the University of Toronto and a clinician-scientist at the University Health Network. His current interests include the unfolded protein response (working with Dr. Brad Wouters), autophagy in prostatic carcinogenesis, translational research in GU and melanoma trials and clinical trial design. He also has an interest in epistemiology in medicine.

Brian Brown, PhD – Dr. Brown is an Assistant Professor in the Departments of Genetics and Genomic Sciences and Gene and Cell Medicine at the The Mount Sinai Medical School, New York. For a number of years, Dr. Brian Brown has been active developing strategies for promoting immunological tolerance. His involvement began with his doctoral studies in Canada and his work with virologist Dr. Frank Graham and hematologist Dr. David Lillicrap to establish ways to overcome the immune response hindering hemophilia gene therapy. He subsequently did his postdoctoral studies in Italy under the supervision of Drs. Luigi Naldini and Maria Grazia Roncarolo, leaders in molecular medicine and immunology. There, he helped develop a new platform for controlling gene expression, which has led to improvements in experimental treatments for hemophilia, cancer, and viral infection. Now, Dr. Brown and his laboratory are applying this strategy to develop ways to prevent type I diabetes.

Ken Lee, MBA – Mr. Lee is a serial biotech entrepreneur with extensive corporate and business development experience. He has over a decade of hands-on experience in preclinical research, clinical research, and bioinformatics. He is the founder and President of iProgen Biotech Inc., a leading pioneer in intracellular protein delivery technology. He was also the founder and President of Helios Bioinformatics Inc. which focused on biological data mining and integration. Mr. Lee holds a MBA from the Richard Ivey School of Business, Advanced Clinical Research Management Certificate from British Columbia Institute of Technology, and an Honor’s degree in Microbiology and Immunology from the University of British Columbia. In addition, he holds professional designations both from the Society of Clinical Research and Regulatory Affairs Professionals Society.

Jeremy Grushcow, PhD, JD – Jeremy is a partner in the Corporate group at Norton Rose OR LLP. His practice focuses on life science, cleantech and other technology-intensive transactions. He has represented pharmaceutical and biotech companies, private equity and VC firms and investment banks in connection with mergers and acquisitions, public and private offerings, licensing deals and other commercial agreements. Prior to joining Norton Rose, Mr. Grushcow practised at Kirkland & Ellis LLP in their Intellectual Property Transactions group and at Shearman & Sterling LLP in their Capital Markets group. Jeremy is the Corporate Secretary to the Board of the Ontario Biosciences Industry Organization (OBIO) and is a member of the Genetics Society of America and the American Association for the Advancement of Science. He is the founder of The Cross-Border Biotech Blog and has authored numerous publications in both legal and scientific journals including Counsel to Counsel, the Journal of Legal Studies and Genetics. Jeremy received a Ph.D. in Molecular Genetics and Cell Biology and a J.D. from the University of Chicago, where he was awarded the John M. Olin Prize, given to the outstanding student in Law and Economics.


© 2016 Armour Therapeutics Inc. All Rights Reserved.